Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
Portfolio Pulse from Vandana Singh
Johnson & Johnson's drug Tremfya shows significant efficacy in treating moderate plaque psoriasis with low body surface area, achieving high clearance rates in a Phase 3b study. Tremfya also received FDA approval for ulcerative colitis, contributing to its $1.01 billion sales in Q3.
October 25, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Tremfya demonstrated significant efficacy in treating moderate plaque psoriasis, achieving high clearance rates in a Phase 3b study. The drug also received FDA approval for ulcerative colitis, contributing to its $1.01 billion sales in Q3.
The positive results from the Phase 3b study and FDA approval for a new indication are likely to boost investor confidence in Tremfya's market potential, positively impacting JNJ's stock. The drug's strong sales performance further supports this outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100